

DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived human LAIR1 protein		
	Human LAIR1 (Gln22-His163) Accession # NP_002278	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus

N-terminal Sequence Analysis No results obtained. Gln22 inferred from enzymatic pyroglutamate treatment revealing Glu23.

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 42 kDa

SPECIFICATIONS

SDS-PAGE	55-65 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When Bovine Collagen I is coated at 10 µg/mL, 100 µL/well, Recombinant Human LAIR1 Fc Chimera binds with an ED ₅₀ of 25-150 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<ul style="list-style-type: none"> ● 12 months from date of receipt, ≤ -20 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, ≤ -20 °C under sterile conditions after reconstitution.

DATA

<p>Binding Activity</p> <p>When Bovine Collagen I is coated at 10 µg/mL, Recombinant Human LAIR-1 Fc Chimera binds with an ED₅₀ of 25-150 ng/mL.</p>	<p>SDS-PAGE</p> <p>2 µg/lane of Recombinant Human LAIR1 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 55-65 kDa and 110-130 kDa, respectively.</p>
--	---

BACKGROUND

LAIR1 (leukocyte-associated Ig-like receptor-1, designated CD305) is an approximately 40 kDa type I transmembrane inhibitory glycoprotein belonging to the Ig superfamily (1-4). LAIR1 is a collagen-binding protein that is expressed in a differentiation- and activation-dependent manner on most immune cells, including T, B, NK and dendritic cells (DC), monocytes, CD34⁺ hematopoietic progenitors, most thymocytes, and selected granulocyte populations (2-7). Mature human LAIR1 is a 266 amino acid (aa) type I transmembrane protein that includes a 144 aa extracellular domain (ECD) with one collagen-binding C2-type Ig-like domain, and a 101 aa cytoplasmic domain with two ITIM motifs (2, 3, 8, 9). Of four potential human LAIR1 splice variants, LAIR1b has a 17 aa deletion within the ECD, but outside the Ig domain. LAIR1c differs from LAIR1b by one aa. LAIR1d has a 78 aa cytoplasmic truncation and lacks ITIM motifs. Human LAIR1 ECD shares <45% aa sequence identity with mouse, rat, bovine or canine LAIR1 ECD, but all are functional orthologs. Humans, but not rodents, also express the 152 aa secreted protein LAIR2, which shares 83% aa sequence identity with the LAIR1 ECD up to aa 140 and can block LAIR1 collagen binding (1, 2). A soluble form of LAIR1 found in plasma and urine also binds collagen (10). Adhesion of LAIR1 to collagens in the extracellular matrix, transmembrane collagens expressed by tumor cells, or antibody-mediated crosslinking of LAIR1, inhibits signals relayed by ITAM-bearing receptors and some cytokine-mediated signals (6-8, 13). Processes that are inhibited include B and T cell receptor-mediated activation, NK and T cell-mediated cytotoxicity, and basophil degranulation (1-4, 8). LAIR1 is reduced or absent on chronic lymphocytic leukemia (CLL) B cells, and some B and DC cells in systemic lupus erythematosus (SLE). Its under-expression potentially enhances CLL proliferation and SLE immune responses (7, 11, 12).

References:

1. Meyaard, L. (2008) *J. Leukoc. Biol.* **83**:799.
2. Meyaard, L. *et al.* (1997) *Immunity* **7**:283.
3. Lebbink, R.J. *et al.* (2004) *J. Immunol.* **172**:5535.
4. Ouyang, W. *et al.* (2003) *Biochem. Biophys. Res. Commun.* **310**:1236.
5. Verbrugge, A. *et al.* (2006) *J. Leukoc. Biol.* **79**:828.
6. Lebbink, R.J. *et al.* (2006) *J. Exp. Med.* **203**:1419.
7. Bonaccorsi, I. *et al.* (2010) *PLoS ONE* **5**:e15080.
8. Tang, X. *et al.* (2009) *J. Immunol.* **182**:5446.
9. Brondijk, T.H.C. *et al.* (2010) *Blood* **115**:1364.
10. Olde Nordkamp, M.J. *et al.* (2011) *Arthritis Rheum.* **63**:3749.
11. Poggi, A. *et al.* (2008) *Leukemia* **22**:980.
12. Colombo, B.M. *et al.* (2012) *PLoS ONE* **7**:e31903.
13. Rygiel, T.P. *et al.* (2011) *Mol. Immunol.* **49**(1-2):402.